Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease

Kaohsiung Medical University

Status: Completed

Conditions: Chronic Liver Disease; Fibrosis

Treatments: Genetic: cytokine polymorphism; Genetic: cytokine; Genetic: cytokine polymorphisms

Study type: Interventional

Funder types: Other

Identifiers

NCT00629603

KMUH-IRB-950347

Details and patient eligibility

About

Hepatitis C virus (HCV) infection causes different disease spectrum ranging from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma. Evidence indicates that host genetic factor may play a role in determining disease progression. It is known that many cytokine polymorphisms affect disease progressin via increasing hepatic fibrosis that are key factors in progressing liver injury. By combinations of fibrosis-relating gene polymorphisms, this study aims to identify patients with high risk for progressive liver disease. These patients need intensive therapy to decrease morbidity and mortality of chronic HCV-related liver disease.

Full description

Determination of the following fibrosis-relating gene polymorphisms in HCV-related chronic liver disease and HCC will be performed: TNF-α , TNF-β, Factor V Leiden, TGF-β1, PDGF-B gene, Angiotensinogen (AT),Angiotensin converting enzyme (ACE), microsomal epoxide hydrolase (mEH) and glutathione-S-transferase (GST).

Enrollment: 600 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with anti-HCV positive

Exclusion criteria

• Anti-HCV-negative patients

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

600 participants in 1 patient group

cytokine polymorphisms, HCV infection

Experimental group

Description:

Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease

Treatment:

Genetic: cytokine polymorphisms

Genetic: cytokine

Genetic: cytokine polymorphism